BPC-157 Dosage Guide

BPC-157 dosing — expressed in micrograms (mcg) per injection or per day — is derived from animal studies, allometric scaling from rodent models to estimated human equivalent doses, and extensive community experience. No human clinical trials have established an official dosing regimen. The commonly used 200–300 mcg range is based on a combination of translated research data and years of anecdotal reporting.

Animal Studies

The majority of BPC-157 research has been conducted in rodent models. Doses in these studies typically range from 10 mcg/kg to 10 mg/kg, administered intraperitoneally, subcutaneously, intragastrically, or applied topically to wounds. Positive results on tendon healing, gastric ulcer repair, and nerve regeneration have been observed across a wide dose range, with most studies using 10–50 mcg/kg.

Allometric Scaling to Human Doses

Community dosing protocols are loosely based on allometric scaling from effective rodent doses. A commonly cited rat dose of 10 mcg/kg, when scaled to a 75 kg human using standard surface area conversion factors, yields approximately 200–300 mcg as a reasonable starting point. This is a rough estimate — not a precise pharmaceutical calculation.

Community & Practitioner Experience

Over the past decade, BPC-157 has become one of the most widely used research peptides for injury recovery. The 250 mcg once or twice daily protocol has emerged as the de facto standard based on thousands of user reports. Some practitioners use weight-based dosing (2.5–5 mcg/kg) for more individualized protocols. Oral protocols for gut healing use higher doses (500–750 mcg/day) to account for reduced bioavailability.

BPC-157 is supplied as a lyophilized (freeze-dried) powder, typically in 5 mg or 10 mg vials. You reconstitute it with bacteriostatic water, then draw your dose using an insulin syringe. The concentration depends on how much water you add to the vial.

Quick Reference — 5 mg Vial

While BPC-157's core mechanism — tissue protection and repair through growth factor upregulation and angiogenesis — is consistent, the optimal dosing protocol varies by the type and severity of the condition being targeted.

Tendon & Ligament Injuries

The most researched and common use case. Animal studies show BPC-157 accelerates tendon-to-bone healing, increases collagen organization, and promotes angiogenesis at the injury site. Commonly used for tendonitis (Achilles, patellar, rotator cuff), ligament sprains, and chronic tendinopathy.

• Dose: 250–500 mcg per day (SubQ)
• Frequency: Once or twice daily
• Injection site: Subcutaneously as close to the injury as practical
• Duration: 4–8 weeks; chronic injuries may need up to 12 weeks

Gut Health & GI Healing

BPC-157's origin in gastric juice makes it particularly relevant for gastrointestinal conditions. Animal studies demonstrate healing of gastric ulcers, protection against NSAID-induced gut damage, and repair of intestinal inflammation (colitis models). Oral dosing is preferred for this application.

• Dose: 500–750 mcg per day (oral preferred)
• Frequency: Once or twice daily on an empty stomach
• Timing: 20–30 minutes before meals
• Duration: 4–8 weeks

Joint Pain & Arthritis

BPC-157 has shown anti-inflammatory and chondroprotective effects in animal models of joint damage. Users report benefits for osteoarthritis-related pain, joint stiffness, and cartilage-related complaints. Injection near the affected joint is standard.

• Dose: 250–300 mcg per day (SubQ)
• Frequency: Once or twice daily
• Injection site: Subcutaneously near the affected joint
• Duration: 4–8 weeks; may be repeated after a break

Post-Surgical Recovery

Some practitioners incorporate BPC-157 into post-surgical recovery protocols to support tissue healing, reduce inflammation, and potentially accelerate return to function. Dosing tends to be on the higher end and is typically started shortly after surgery (once cleared by the surgeon).

• Dose: 250–500 mcg per day (SubQ)
• Frequency: Twice daily
• Injection site: Near the surgical site (if accessible) or abdominal SubQ
• Duration: 4–8 weeks or as guided by the treatment provider

General Recovery & Wellness

Some users take BPC-157 at lower doses for general recovery support — reduced soreness from training, faster recovery from minor strains, and overall tissue maintenance. This is the least studied application and relies primarily on community reports.

• Dose: 150–250 mcg per day (SubQ)
• Frequency: Once daily
• Injection site: Abdominal subcutaneous (general systemic effect)
• Duration: 4–6 weeks, followed by a break

BPC-157 is typically used in defined cycles rather than continuously. Most protocols run 4–8 weeks, with some users taking breaks between cycles. There is no established evidence of tolerance with BPC-157, but cycling is standard practice in the community.

Time of Day

• Once daily: Morning is most common; some users prefer evening. Consistency matters more than the specific time of day.
• Twice daily: Split doses 8–12 hours apart (e.g., morning and evening) to maintain more stable peptide levels.
• Oral dosing: Take on an empty stomach, 20–30 minutes before a meal, for best GI tract exposure.
• No strict timing requirement — BPC-157 does not need to be timed around meals, workouts, or sleep (except for oral dosing).

Common Side Effects

Mild and generally transient (reported by a minority of users):

• Nausea — more common with oral dosing, usually resolves within days
• Dizziness or lightheadedness — typically mild and short-lived
• Injection site redness, soreness, or minor swelling
• Headache — occasionally reported in the first few days of use
• Fatigue or mild lethargy — uncommon and usually temporary

Rare:

• Hot or cold flashes — reported anecdotally, mechanism unclear
• Changes in blood pressure — BPC-157 interacts with the NO system, which modulates vascular tone

Contraindications

• Active cancer or history of cancer — BPC-157 promotes angiogenesis (new blood vessel formation). While no studies have demonstrated tumor-promoting effects, the theoretical concern exists that enhanced angiogenesis could support tumor growth. Avoid use with active malignancies.
• Pregnancy and breastfeeding — no safety data exists for BPC-157 during pregnancy or nursing. Avoid use entirely.
• Active infections at the injection site — do not inject through infected, inflamed, or broken skin.
• Anticoagulant therapy — BPC-157 may interact with the NO system and platelet function. Exercise caution if taking blood thinners and consult your healthcare provider.

Drug Interactions

• NSAIDs: BPC-157 has shown protective effects against NSAID-induced gastric damage in animal studies. Some users specifically combine BPC-157 with NSAIDs to mitigate gut side effects, though this is not clinically validated.
• Blood thinners (warfarin, heparin, DOACs): Potential interaction via the NO system. Use with caution and medical supervision.
• Dopaminergic drugs: BPC-157 interacts with the dopamine system in animal models. If taking dopamine agonists or antagonists, consult your healthcare provider.

When to Stop

• Persistent nausea, vomiting, or GI distress that does not resolve within 3 days
• Signs of infection at the injection site (increasing redness, heat, pus, fever)
• Unexplained swelling, rash, or allergic-type reaction
• Any symptom that feels unusual or concerning — err on the side of caution